[{"indications": "Indications\u00a0hypertension; renal disease in hypertensive type 2 diabetes mellitus\r\n(see also notes above)", "name": "IRBESARTAN With diuretic", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.5 Hypertension and heart failure", "2.5.5 Drugs affecting the renin-angiotensin system", "2.5.5.2 Angiotensin-II receptor antagonists", "IRBESARTAN", "With diuretic"], "cautions": "Cautions\u00a0\n(From 2.5.5.2 Angiotensin-II receptor antagonists: British National Formulary)\nCautions\u00a0Angiotensin-II receptor antagonists should be used with caution in renal artery stenosis (see also Renal Effects under ACE Inhibitors, section 2.5.5.1). Monitoring of plasma-potassium concentration is advised, particularly in the elderly and in patients with renal impairment; lower initial doses may be appropriate in these patients. Angiotensin-II receptor antagonists should be used with caution in aortic or mitral valve stenosis and in hypertrophic cardiomyopathy. Those with primary aldosteronism, and Afro-Caribbean patients (particularly those with left ventricular hypertrophy), may not benefit from an angiotensin-II receptor antagonist. Interactions: Appendix 1 (angiotensin-II receptor antagonists).", "side-effects": "Side-effects\u00a0see notes above; also nausea, vomiting; fatigue;\r\nmusculoskeletal pain; less commonly diarrhoea, dyspepsia,\r\nflushing, tachycardia, chest pain, cough, and sexual dysfunction; rarely rash, urticaria; very rarely headache,\r\nmyalgia, arthralgia, tinnitus, taste disturbance, hepatitis, renal\r\ndysfunction, and cutaneous vasculitis", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/89563.htm", "doses": ["Hypertension, initially 150\u00a0mg once daily, increased if\r\nnecessary to 300\u00a0mg once daily (in haemodialysis or in elderly over 75 years, initial dose of 75\u00a0mg once\r\ndaily may be used); child not recommended", "Renal disease in hypertensive type 2 diabetes mellitus, initially\r\n150\u00a0mg once daily, increased to 300\u00a0mg once daily if tolerated (in\r\nhaemodialysis or in elderly over 75\r\nyears, consider initial dose of 75\u00a0mg once daily); child not recommended", "Name[CoAprovel\u00ae (Bristol-Myers Squibb) (Sanofi-Aventis) ] Tablets, f/c, irbesartan 150\u00a0mg, hydrochlorothiazide 12.5\u00a0mg (peach),\r\nnet price 28-tab pack = \u00a311.84; irbesartan 300\u00a0mg, hydrochlorothiazide 12.5\u00a0mg (peach), 28-tab pack = \u00a315.93;\r\nirbesartan 300\u00a0mg, hydrochlorothiazide 25\u00a0mg (pink), 28-tab pack =\r\n\u00a315.93"], "pregnancy": "Pregnancy\u00a0\n(From 2.5.5.2 Angiotensin-II receptor antagonists: British National Formulary)\nPregnancy\u00a0Angiotensin-II receptor antagonists should be avoided in pregnancy unless essential. They may adversely affect fetal and neonatal blood pressure control and renal function; skull defects and oligohydramnios have also been reported."}, {"indications": "Indications\u00a0hypertension; renal disease in hypertensive type 2 diabetes mellitus\r\n(see also notes above)", "name": "IRBESARTAN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.5 Hypertension and heart failure", "2.5.5 Drugs affecting the renin-angiotensin system", "2.5.5.2 Angiotensin-II receptor antagonists", "IRBESARTAN"], "cautions": "Cautions\u00a0\n(From 2.5.5.2 Angiotensin-II receptor antagonists: British National Formulary)\nCautions\u00a0Angiotensin-II receptor antagonists should be used with caution in renal artery stenosis (see also Renal Effects under ACE Inhibitors, section 2.5.5.1). Monitoring of plasma-potassium concentration is advised, particularly in the elderly and in patients with renal impairment; lower initial doses may be appropriate in these patients. Angiotensin-II receptor antagonists should be used with caution in aortic or mitral valve stenosis and in hypertrophic cardiomyopathy. Those with primary aldosteronism, and Afro-Caribbean patients (particularly those with left ventricular hypertrophy), may not benefit from an angiotensin-II receptor antagonist. Interactions: Appendix 1 (angiotensin-II receptor antagonists).", "side-effects": "Side-effects\u00a0see notes above; also nausea, vomiting; fatigue;\r\nmusculoskeletal pain; less commonly diarrhoea, dyspepsia,\r\nflushing, tachycardia, chest pain, cough, and sexual dysfunction; rarely rash, urticaria; very rarely headache,\r\nmyalgia, arthralgia, tinnitus, taste disturbance, hepatitis, renal\r\ndysfunction, and cutaneous vasculitis", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/64890.htm", "doses": ["Hypertension, initially 150\u00a0mg once daily, increased if\r\nnecessary to 300\u00a0mg once daily (in haemodialysis or in elderly over 75 years, initial dose of 75\u00a0mg once\r\ndaily may be used); child not recommended", "Renal disease in hypertensive type 2 diabetes mellitus, initially\r\n150\u00a0mg once daily, increased to 300\u00a0mg once daily if tolerated (in\r\nhaemodialysis or in elderly over 75\r\nyears, consider initial dose of 75\u00a0mg once daily); child not recommended"], "pregnancy": "Pregnancy\u00a0\n(From 2.5.5.2 Angiotensin-II receptor antagonists: British National Formulary)\nPregnancy\u00a0Angiotensin-II receptor antagonists should be avoided in pregnancy unless essential. They may adversely affect fetal and neonatal blood pressure control and renal function; skull defects and oligohydramnios have also been reported."}]